Finjan Receives Three Decisively Favorable Final Written

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
116
Finjan Receives Three Decisively Favorable Final Written PTAB Decisions

EAST PALO ALTO, CA--(Marketwired - Mar 21, 2017) - Finjan Holdings, Inc. (NASDAQ: FNJN), a cybersecurity company, and its subsidiary Finjan, Inc. ("Finjan") announced that on March 16 and 17, 2017, the Patent Trial and Appeal Board ("PTAB") for the United States Patent & Trademark Office ("USPTO") ruled against Palo Alto Networks, Inc. ("PANW") petitions for three Inter Partes Reviews ("IPRs"). Case No. IPR2015-01974 challenged Finjan's U.S. Patent 7,647,633 and Case Nos. IPR2015-02001 and IPR2016-00157 challenged Finjan's U.S. Patent 8,225,408. Blue Coat Systems, Inc. ("Blue Coat") joined all three of these petitions so these PTAB decisions apply to its challenges as well.

In IPR2015-01974, the PTAB instituted a review on only two of the twelve challenged claims against the '633 Patent and, as a whole, found all challenged claims valid and patentable. In IPR2015-02001 and IPR2016-00157, the PTAB consolidated the petitions and instituted a review on twenty claims of the '408 Patent and, once again, found all challenged claims to be both valid and patentable.

Summary of IPRs Instituted

Patent and Case Number   Petitioner   Decision
U.S. Patent No. 8,141,154
IPR-2015-01892
  PANW joined by Symantec   Not unpatentable (no changes)
U.S. Patent No. 8,141,154
IPR2016-00151
  PANW joined by Symantec   Not unpatentable (no changes)
U.S. Patent No. 8,677,494
IPR2015-01892
  Symantec joined by Blue Coat   Partially Denied/Partially Granted (1 method claim unpatentable)
US Patent No. 7,647,633
IPR2015-01974
  PANW joined by Blue Coat   Not unpatentable (no changes)
US Patent No. 8,225,408
IPR2015-02001
  PANW joined by Blue Coat   Not unpatentable (no changes)
US Patent No. 8,225,408
IPR2016-00157
  PANW joined by Blue Coat   Not unpatentable (no changes)
US Patent No. 8,677,494
IPR2016-00159
  PANW joined by Blue Coat   Pending

Finjan has pending district court actions or appeals against Palo Alto Networks, Inc., Symantec Corporation, Blue Coat Systems, Inc., FireEye, Inc., Sophos, Inc., ESET and its affiliates, Cisco Systems, Inc., and Avast Software, relating to, collectively, more than 20 patents in the Finjan portfolio. The court dockets for the foregoing cases are publicly available on the Public Access to Court Electronic Records (PACER) website, www.pacer.gov, which is operated by the Administrative Office of the U.S. Courts.

ABOUT FINJAN
Established nearly 20 years ago, Finjan is a globally recognized leader in cybersecurity. Finjan's inventions are embedded within a strong portfolio of patents focusing on software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan continues to grow through investments in innovation, strategic acquisitions, and partnerships promoting economic advancement and job creation. For more information, please visit www.finjan.com.

Follow Finjan Holdings, Inc.:
Twitter: @FinjanHoldings
LinkedIn: linkedin.com/company/finjan

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, the matters set forth herein that are forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. Potential risks and uncertainties include, but are not limited to, Finjan's expectations and beliefs regarding Finjan's licensing program, the outcome of pending or future enforcement actions, the granting of Inter Partes Review (IPR) of our patents or an unfavorable determination pursuant to an IPR or other challenges at the USPTO of our patents, the enforceability of our patents, the cost of litigation, the unpredictability of our cash flows, our ability to expand our technology and patent portfolio, the continued use of our technologies in the market, our stock price, changes in the trading market for our securities, regulatory developments, general economic and market conditions, the market acceptance and successful business, technical and economic implementation of Finjan Holdings' intended operational plan; and the other risk factors set forth from time to time in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2015, and the Company's periodic filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from Finjan Holdings, Inc. All forward-looking statements herein reflect our opinions only as of the date of this release. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Finjan Holdings undertakes no obligation, and expressly disclaims any obligation, to update forward-looking statements herein in light of new information or future events.

Investor Contact:
Vanessa Winter | Finjan
Valter Pinto | KCSA Strategic Communications
(650) 282-3245
investors@finjan.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 3

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading

Top 5 Most Recently Viewed Articles

SBVA Triumphs as Venture Capital Leader in Prestigious Award

Updated Category News Views 194

SBVA Achieves Prestigious Recognition SBVA, formerly known as SoftBank Ventures Asia, recently earned the esteemed title of "VC of the Year" at the annual Korea Venture Capital Awards. This significant honor highlights SBVA's remarkable investment performances and its vital role in enhancing the venture ecosystem. The Importance of the Korea Venture Capital Awards The...

Continue Reading
Strategic Acquisition: TopBuild Expands with Metro Supply Company

Updated Category News Views 116

Strategic Acquisition by TopBuild TopBuild Corp. (NYSE:BLD), a leader in insulation installation and specialty distribution for the construction sector, has recently made a significant move by agreeing to acquire Metro Supply Company. This acquisition is set to enhance TopBuild’s offerings in the commercial and industrial insulation market and is expected to bring in...

Continue Reading
Key Class Action Update on MoonLake Immunotherapeutics (MLTX)

Updated Category News Views 117

MoonLake Immunotherapeutics Faces Class Action Lawsuit Investors should be aware that MoonLake Immunotherapeutics (NASDAQ: MLTX) is currently facing a class action lawsuit due to alleged violations of securities laws. The DJS Law Group is actively reminding shareholders of their rights in light of this legal action, emphasizing the importance of staying informed during...

Continue Reading
Columbus McKinnon Set to Shine at Global Industrial Conference

Updated Category News Views 119

Columbus McKinnon Corporation's Participation in a Key Event Columbus McKinnon Corporation (Nasdaq: CMCO), a prominent name in the design and manufacturing of motion solutions, is excited to announce its participation in an upcoming event that is significant for the industry. The company will showcase its expertise at the Baird Global Industrial Conference. This important...

Continue Reading
The Growth of a $100 Investment in Norfolk Southern Over 20 Years

Updated Category News Views 64

The Benefits of Long-Term Investments in Norfolk Southern Investing wisely can truly change your financial landscape, and Norfolk Southern (NYSE: NSC) is a stellar example of this. Over the last 20 years, investing in NSC has yielded remarkable results, achieving an annualized growth rate of 5.31%. This outstanding performance has led to an impressive average annual...

Continue Reading